22 abstracts spanning its full portfolio. Highlights included late-breaking data for nemolizumab showing clinically meaningful benefits in children aged 2 to 11 with moderate-to-severe atopic dermatitis. These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities. It also represents a significant opportunity to improve patient lives, with up to 25% of children affected by atopic dermatitis and the currently limited approved treatment options for children living with moderate-to severe atopic dermatitis.

At 2026 Winter Clinical™ Miami, interim results from the OLYMPIA long-term extension study showed Nemluvio maintained disease control in prurigo nodularis for up to three years, with clinically meaningful improvements in itch intensity, skin lesions, and quality of life – the longest extension study in pr
=*=*=*=*=*=
当前为第10/27页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页